- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03624478
Hypofractionated Radiation Therapy in Treating Participants With Breast Cancer Before Surgery
A Pilot/Phase II Trial of Hypofractionated Radiotherapy to the Whole Breast Alone Before Breast Conserving Surgery
Study Overview
Status
Conditions
- Anatomic Stage I Breast Cancer AJCC v8
- Anatomic Stage IA Breast Cancer AJCC v8
- Anatomic Stage IB Breast Cancer AJCC v8
- Anatomic Stage IIA Breast Cancer AJCC v8
- Prognostic Stage I Breast Cancer AJCC v8
- Prognostic Stage IA Breast Cancer AJCC v8
- Prognostic Stage IB Breast Cancer AJCC v8
- Prognostic Stage IIA Breast Cancer AJCC v8
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the pathologic complete response (pCR) rate after hypofractionated radiotherapy to the whole breast alone, based on the postsurgical specimen.
SECONDARY OBJECTIVES:
I. To evaluate acute and late toxicity with preoperative radiation including grade >= 2 pneumonitis.
II. To estimate the 5-year locoregional control, distant recurrence, invasive disease-free survival, cause-specific survival, and overall survival.
CORRELATIVE AND EXPLORATORY OBJECTIVES:
I. To evaluate patient-reported outcomes. II. To evaluate clinical features, treatment technique, dose-volume parameters, histologic and genetic variants associated with adverse events, and fair and poor cosmetic outcomes or unplanned surgical intervention.
III. Evaluate tumor mutation signatures before and after radiation; correlate tumor mutation signatures before and after radiation with pathologic information at the time of surgery.
IV. To describe the pathologic changes seen in breast cancer patients with preoperative radiation.
OUTLINE:
Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
After completion of study treatment, participants are followed up at 12 weeks, 6, 12, 24, and 36 months, and 5 years after radiation therapy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85259
- Mayo Clinic in Arizona
-
-
Florida
-
Jacksonville, Florida, United States, 32224-9980
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histological confirmation of breast cancer
- Clinical stage T0-T2 N0 M0
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 2
- Able to and provides Institutional Review Board (IRB) approved study specific written informed consent
- Study entry must be within 120 days of last biopsy (breast)
- Able to complete all mandatory tests
- Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
- Planned breast surgery and indications for whole breast radiotherapy
Exclusion Criteria:
- Medical contraindication to receipt of radiotherapy
- Severe active co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or providing informed consent
- Active systemic lupus or scleroderma
- Pregnancy
- Women of childbearing potential who are unwilling to employ adequate contraception
- Prior receipt of ipsilateral breast or chest wall radiation
- Recurrent breast cancer
- Indications for comprehensive regional nodal irradiation
- No neo-adjuvant therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (hypofractionated radiation therapy)
Participants undergo hypofractionated radiation therapy daily for 5 days, then undergo standard of care surgery 4-16 weeks after radiation therapy.
|
Undergo hypofractionated radiation therapy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic Complete Response (pCR) Rate Defined as a Residual Tumor Burden of 0-1 in the Surgical Specimen
Time Frame: up to 2 years
|
The proportion of successes (number of patients achieving pCR at time of definitive surgery) will be estimated by the number of successes divided by the total number of evaluable patients.
Confidence intervals for the true success proportion will be calculated according to the approach of Duffy and Santner.
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Acute Adverse Events (AE)
Time Frame: Up to 180 days post radiation therapy
|
The maximum grade for each type of acute AE will be recorded for each patient.
Data will be summarized as frequencies and relative frequencies.
Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
|
Up to 180 days post radiation therapy
|
Incidence of Late Adverse Events
Time Frame: Up to 5 years post radiation therapy
|
The maximum grade for each type of late AE will be recorded for each patient.
Data will be summarized as frequencies and relative frequencies by treatment arm.
Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.
|
Up to 5 years post radiation therapy
|
Locoregional Control
Time Frame: Up to 5 years
|
The cumulative incidence of locoregional recurrence will be estimated using a competing risks method (Gooley et al.).
The competing risks will be distant breast cancer recurrence and death.
|
Up to 5 years
|
Invasive Disease-free Survival
Time Frame: From registration until the time of disease recurrence or death due to any cause, assessed up to 5 years
|
Will be estimated with a Kaplan-Meier estimator and curve.
Estimates will be given for specific time points along with 95% confidence intervals (CIs).
|
From registration until the time of disease recurrence or death due to any cause, assessed up to 5 years
|
Distant Recurrence
Time Frame: Up to 5 years
|
Up to 5 years
|
|
Disease- Free Survival
Time Frame: From registration until the time of disease recurrence or death due to any cause, assessed up to 5 years
|
Will be estimated with a Kaplan-Meier estimator and curve.
Estimates will be given for specific time points along with 95% CIs.
|
From registration until the time of disease recurrence or death due to any cause, assessed up to 5 years
|
Cause-specific Survival
Time Frame: From registration to death due to breast cancer assessed up to 5 years
|
Will be estimated with a Kaplan-Meier estimator and curve.
Estimates will be given for specific time points along with 95% CIs.
|
From registration to death due to breast cancer assessed up to 5 years
|
Overall Survival
Time Frame: From registration to death due to any cause assessed up to 5 years
|
Will be estimated with a Kaplan-Meier estimator and curve.
Estimates will be given for specific time points along with 95% CIs.
|
From registration to death due to any cause assessed up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Self-reporting of Toxicities
Time Frame: Up to 5 years
|
The subscales of the Breast Cancer Treatment Outcomes Scale (BCTOS), elements from Patient Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and other patient reported measures such as fatigue, breast pain, breast shape, and arm related morbidity outlined in the appendix will be summarized as the mean +/- SD and median (minimum value, maximum value).
Scale score trajectories over time will be examined using stream plots and mean plots with standard deviation error bars overall.
Analysis will include percent change from baseline using t-tests and generalized linear models to test for changes at each time point and non-zero slope respectfully.
|
Up to 5 years
|
Patient Self-reported Cosmetic Outcomes
Time Frame: Baseline up to 5 years
|
Assessed using a modified Harvard Cosmesis Scale and the BCTOS.
The values of the cosmesis instruments (patient self-reported and panel-assessed) will be summarized with the frequencies and confidence intervals of fair or poor cosmesis events.
|
Baseline up to 5 years
|
Panel Assessed Cosmetic Outcome
Time Frame: Baseline up to 2 years
|
Cosmesis will be assessed by a panel of breast cancer medical providers using digital photographs.
|
Baseline up to 2 years
|
Clinical Features, Treatment Technique, Dose-volume Parameters, Histologic and Genetic Variants
Time Frame: Up to 5 years
|
Associated with adverse events, and fair and poor cosmetic outcomes or unplanned surgical intervention.
|
Up to 5 years
|
Tumor Mutation Signatures
Time Frame: Up to 5 years
|
Will be analyzed before and after radiotherapy as compared to pathologic information at the time of surgery.
Continuous variable will be compared using unpaired t tests and nominal variables will be compared using contingency tables and Chi square analyses.
|
Up to 5 years
|
Pathologic Changes Seen in Breast Cancer Patients With Preoperative Radiation
Time Frame: Up to 5 years
|
Will be described.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Carlos E. Vargas, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MC1732 (Other Identifier: Mayo Clinic in Arizona)
- NCI-2018-01606 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 17-004130 (Other Identifier: Mayo Clinic Institutional Review Board)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anatomic Stage I Breast Cancer AJCC v8
-
M.D. Anderson Cancer CenterCompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of California, San FranciscoTerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingBreast Cancer | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
University of WashingtonUnited States Department of DefenseRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedBreast Cancer | Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer... and other conditionsUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
Clinical Trials on Hypofractionated Radiation Therapy
-
University of UtahNational Cancer Institute (NCI)RecruitingCervical Carcinoma | Endometrial CarcinomaUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina
-
University of UtahActive, not recruitingStage 0 Breast Cancer | Stage I Breast Cancer | Stage II Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma In SituUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8United States
-
Samsung Medical CenterRecruitingRadiotherapy Side EffectKorea, Republic of
-
Postgraduate Institute of Medical Education and...Completed
-
Cancer Trials IrelandCompleted
-
University Hospital, GhentNationaal KankerplanTerminatedInoperable Early Stage Non-small Cell Lung CancerBelgium
-
University of Colorado, DenverActive, not recruitingBreast CancerUnited States
-
Changhai HospitalRecruiting